Skip to search formSkip to main contentSkip to account menu

cerdulatinib

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Rapid and Durable Responses with the SYK/JAK Inhibitor Cerdulatinib in a Phase 2 Study in Relapsed/Refractory Follicular Lymphoma-Alone or in Combination with Rituximab
Background: Despite recent advances, follicular lymphoma (FL) remains incurable for most patients. Relapsed/refractory (r/r) FL… 
2019
2019
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID AND DURABLE TUMOR RESPONSES IN A PHASE 2 STUDY IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA - AS A SINGLE AGENT AND COMBINED WITH RITUXIMAB…
2018
2018
The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).
7511Background: Cerdulatinib is a selective, potent inhibitor of SYK, JAK1, JAK3, and TYK2. Preclinical and clinical data suggest… 
2017
2017
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN a PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL MALIGNANCIES
fold. Renal clearance accounted for 34% of apparent oral clearance. Conclusions: Our data suggest TAK‐659 is generally well… 
2017
2017
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study
Abstract Preclinical studies suggest that the spleen tyrosine kinase (SYK) and Janus kinase (JAK) family members can contribute… 
Review
2016
Review
2016
Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines
Abnormal upregulation of NFκB activity is observed in a variety of B cell malignancies, resulting in proliferative and survival… 
2016
2016
Abstract CT144: Preclinical and clinical studies and modeling and simulation to identify phase II dose for cerdulatinib: a dual SYK/JAK inhibitor for the treatment of B-cell malignancies
Background. Subsets of B cell lymphomas appear to rely on B-cell receptor (BCR) and/or cytokine JAK/STAT signaling for survival… 
2016
2016
Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies—Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD…
7557Background: Subsets of B cell malignancies demonstrate a reliance on BCR and/or cytokine JAK/STAT signaling for survival… 
2015
2015
The Syk\Jak Inhibitor Cerdulatinib (PRT062070) Shows Promising Preclinical Activity in Chronic Lymphocytic Leukemia By Antagonising B Cell Receptor and Microenvironmental Signalling
The emergence of B cell receptor (BCR) kinase inhibitors has proved effective for the treatment of a number of B-cell… 
2014
2014
SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor
Non-Hodgkin Lymphoma (NHL) represents about 5 percent of all cancers diagnosed in the United States. While incidence of NHL has… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)